ANI Pharmaceuticals (ANIP) announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI’s Pimozide Tablets is the generic version of the reference listed drug Orap. U.S. annual sales for Pimozide Tablets total approximately $3.1M, based on February 2026 moving annual total IQVIA data.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals launches Isosorbide Mononitrate Tablet USP
- ANI Pharmaceuticals announces publication of iluvien clinical trial results
- ANI Pharmaceuticals Highlights Updated Non-GAAP Metrics to Investors
- ANI Pharmaceuticals Signals Strong Growth in 2025 Call
- ANI Pharmaceuticals Posts Record 2025 Results on Rare Disease Growth